endocrinology
Type 2 diabetes

Cardiovascular benefits of SGLT2 inhibitors may override risk of harm

The cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors are likely to override the risk of harm in many patients with type 2 diabetes, a new study has found. However the large systematic review and meta-analysis published online in The Lancet Diabetes & Endocrinology, highlighted significant side effects including increased genital infections, and called for some ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic